Aegle Therapeutics Receives Rare Pediatric Disease Designation from the Food and Drug Administration (FDA) for AGLE-102 for Patients with Dystrophic Epidermolysis Bullosa
- Tuesday, October 6, 2020, 7:00
- Finance
- Add a comment
BOSTON and MIAMI, Oct. 6, 2020 /PRNewswire/ — Aegle Therapeutics Corporation, a first-in-class biotechnology company committed to delivering cell-free therapy to patients affected by severe dermatological conditions, today announced that the FDA has granted Rare Pediatric Disease (RPD)…
About the Author
adminasapcorp has written 41538 stories on this site.